US20080070975A1 - Formulations for parenteral delivery of compounds and uses thereof - Google Patents

Formulations for parenteral delivery of compounds and uses thereof Download PDF

Info

Publication number
US20080070975A1
US20080070975A1 US11/890,034 US89003407A US2008070975A1 US 20080070975 A1 US20080070975 A1 US 20080070975A1 US 89003407 A US89003407 A US 89003407A US 2008070975 A1 US2008070975 A1 US 2008070975A1
Authority
US
United States
Prior art keywords
methylnaltrexone
brl brl
calcium
brl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/890,034
Other languages
English (en)
Inventor
Syed Shah
Christian Ofslager
Mahdi Fawzi
Natalyia Bazhina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080070975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/890,034 priority Critical patent/US20080070975A1/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of US20080070975A1 publication Critical patent/US20080070975A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAZHINA, NATALYIA, SHAH, SYED M., OFSLAGER, CHRISTIAN, FAWZI, MAHDI B.
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAZHINA, NATALIYA
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAZHINA, NATALIYA
Priority to US12/726,113 priority patent/US20100249169A1/en
Priority to US14/105,805 priority patent/US20150025100A1/en
Priority to US15/158,967 priority patent/US20160338946A1/en
Priority to US16/514,722 priority patent/US20200179270A1/en
Priority to US17/357,023 priority patent/US20220023200A1/en
Priority to US18/244,446 priority patent/US20230414490A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Opioids are widely used in patients with advanced cancers and other terminal diseases to lessen suffering. Opioids are narcotic medications that activate opioid receptors located in the central nervous system to relieve pain. Opioids, however, also react with receptors outside of the central nervous system, resulting in side effects including constipation, nausea, vomiting, urinary retention and severe itching. Most notable are the effects in the gastrointestinal tract (GI) where opioids inhibit gastric emptying and propulsive motor activity of the intestine, thereby decreasing the rate of intestinal transit which can produce constipation. The effectiveness of opioids for pain is often limited due to resultant side effects, which can be debilitating and often cause patients to cease use of opioid analgesics.
  • GI gastrointestinal tract
  • endogenous opioid compounds and receptors may also affect activity of the gastrointestinal (GI) tract and may be involved in normal regulation of intestinal motility and mucosal transport of fluids in both animals and man.
  • GI gastrointestinal
  • researchers have suggested that endogenous opioid compounds and receptors may also affect activity of the gastrointestinal (GI) tract and may be involved in normal regulation of intestinal motility and mucosal transport of fluids in both animals and man.
  • bowel dysfunction such as post-operative (or post-surgical) ileus
  • bowel dysfunction such as post-operative (or post-surgical) ileus
  • women who have recently given birth commonly suffer from postpartum ileus, which is thought to be caused by similar natural opioid fluctuations as a result of birthing stress.
  • Bowel dysfunction associated with post-operative or post partum ileus can typically last for 3 to 5 days, with some severe cases lasting more than a week.
  • Administration of opioid analgesics to a patient after surgery which is now an almost universal practice, may exacerbate bowel dysfunction, thereby delaying recovery of normal bowel function, prolonging hospital stays, and increasing medical care costs.
  • Opioid antagonists such as naloxone, naltrexone, and nalmefene, have been studied as a means of antagonizing undesirable peripheral effects of opioids.
  • these agents act not only on peripheral opioid receptors, but also on central nervous system sites, so that they sometimes reverse the beneficial analgesic effects of opioids, or cause symptoms of opioid withdrawal.
  • Preferable approaches for use in controlling opioid-induced side effects include use of peripheral opioid antagonist compounds that do not readily cross the blood-brain barrier.
  • the peripheral ⁇ opioid antagonist compound methylnaltrexone and related compounds have been disclosed for use in curbing opioid-induced side effects in patients (e.g., constipation, pruritus, nausea, and/or vomiting).
  • methylnaltrexone in certain mediums and under certain conditions has been found to form degradation products. For example, see US 2004266806A1. It is desirable to provide dosage forms that are capable of effective delivery of methylnaltrexone without extensive degradation of the methylnaltrexone under refrigeration and/or room temperature conditions.
  • the present invention provides certain methylnaltrexone formulations.
  • the invention provides formulations having improved shelf-life stability characteristics of active compound under refrigeration as well as at room temperature conditions.
  • Provided formulations are useful for parenteral administration of methylnaltrexone.
  • the invention includes methods for production and use of such formulations, as well as products and kits containing provided formulations.
  • a pharmaceutical composition containing an effective amount of at least one active compound selected from at least methylnaltrexone, or a pharmaceutically acceptable salt thereof, and a calcium salt chelating agent in an aqueous solution.
  • liquid formulations containing methylnaltrexone, or a pharmaceutically acceptable salt thereof, a calcium salt, a chelating agent, an isotonic agent, and an aqueous solvent are provided.
  • a calcium salt and a chelating agent are provided together as a calcium salt chelating agent.
  • a calcium salt chelating agent is selected from calcium ethylenediaminetetraacetic acid (EDTA), calcium diethylenetriaminepentaacetic acid (DTPA), calcium hydroxyethylenediaminetriacetic acid (HEDTA), calcium ethylene glycol-bis-(2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA), calcium nitrilotriacetic acid (NTA), calcium citrate, and calcium salt derivatives thereof.
  • a calcium salt chelating agent is calcium EDTA.
  • formulations further comprise an additional stabilizing agent.
  • a stabilizing agent is selected from glycine, benzoic acid, citric, glycolic, lactic, malic, and maleic acid.
  • a stabilizing agent is glycine.
  • a formulation comprises methylnaltrexone or a pharmaceutically acceptable salt thereof, a calcium chelating agent, a stabilizing agent, an isotonic agent, and an aqueous solvent.
  • a formulation comprises methylnaltrexone or a pharmaceutically acceptable salt thereof, calcium EDTA, glycine, and sodium chloride, in an aqueous solution.
  • provided formulations are useful for preventing, treating or reducing severity of side effects resulting from use of opioids, including inhibition of gastrointestinal dysfunction (e.g., constipation, bowel hypomotility, impaction, gastric hypomotility, GI sphincter constriction, increased sphincter tone, inhibition of gastrointestinal motility, inhibition of intestinal motility, inhibition of gastric emptying, delayed gastric emptying, incomplete evacuation, nausea, emesis (vomiting), bloating, abdominal distension), cutaneous flushing, sweating, dysphoria, pruritis, urinary retention, etc.
  • gastrointestinal dysfunction e.g., constipation, bowel hypomotility, impaction, gastric hypomotility, GI sphincter constriction, increased sphincter tone
  • inhibition of gastrointestinal motility inhibition of intestinal motility
  • inhibition of gastric emptying inhibition of gastric emptying
  • delayed gastric emptying delayed gastric emptying
  • bloating abdominal distension
  • formulations are useful for administration to patients receiving short term opioid treatment (e.g., patients recovering from surgery (abdominal, orthopedic, surgery from trauma injuries etc.), patients recovering from trauma injuries, and patients recovering from child birth).
  • Formulations are also useful for administration to subjects receiving chronic opioid administration (e.g., terminally ill patients receiving opioid therapy (e.g., an AIDS patient, a cancer patient, a cardiovascular patient); subjects receiving chronic opioid therapy for pain management (e.g., back pain); subjects receiving opioid therapy for maintenance of opioid withdrawal).
  • chronic opioid administration e.g., terminally ill patients receiving opioid therapy (e.g., an AIDS patient, a cancer patient, a cardiovascular patient); subjects receiving chronic opioid therapy for pain management (e.g., back pain); subjects receiving opioid therapy for maintenance of opioid withdrawal).
  • Additional uses of provided formulations include prevention, treatment or reduction of severity of symptoms associated with disorders or conditions resulting from normal or aberrant activity of endogenous opioids.
  • disorders or conditions include, among others, ileus (e.g., post-partum ileus, paralytic ileus), gastrointestinal dysfunction that develops following abdominal surgery (e.g., colectomy, including but not limited to, right hemicolectomy, left hemicolectomy, transverse hemicolectomy, colectomy takedown, and low anterior resection) such as post-operative ileus, and idiopathic constipation.
  • formulations are also useful in treatment of conditions including, for example, cancers involving angiogenesis, inflammatory disorders (e.g., irritable bowel disorder), immune suppression, cardiovascular disorders (e.g., bradycardia, hypotension) chronic inflammation and/or chronic pain, sickle cell anemia, vascular wounds, and retinopathy, decreased biliary secretion, decreased pancreatic secretion, biliary spasm, and increased gastroesophageal reflux.
  • inflammatory disorders e.g., irritable bowel disorder
  • immune suppression e.g., bradycardia, hypotension
  • cardiovascular disorders e.g., bradycardia, hypotension
  • chronic inflammation and/or chronic pain e.g., sickle cell anemia, vascular wounds, and retinopathy
  • decreased biliary secretion decreased pancreatic secretion
  • biliary spasm e.g., decreased pancreatic secretion, biliary spasm
  • FIG. 1A and FIG. 1B Effect of CaEDTA and NaEDTA on the formation of 2′,2-bis methylnaltrexone in the presence of iron at 40° C. ( FIG. 1A ) and room temperature, 25° ( FIG. 1B ). Both calcium EDTA and sodium EDTA are effective inhibitors of formation of the 2′,2′ bis methylnaltrexone degradant.
  • FIGS. 2A, 2B , 2 C, and 2 D Effect of CaEDTA on the formation of 7-dihydroxy methylnaltrexone in solutions.
  • Calcium EDTA but not sodium EDTA is an effective inhibitor of formation of the 7-dihydroxy-methylnaltrexone degradant.
  • the effect of CaEDTA on the formation of 7-dihydroxy methylnaltrexone in solution following one month storage at room temperature ( FIG. 2C ) and at 40° C. ( FIG. 2D ) was assessed.
  • the presence of CaEDTA reduced formation of 7-dihydroxy methylnaltrexone at either temperature. After one month at room temperature, the level was reduced from 0.34% to 0.11%; and at 40° C./75% RH, the level was reduced from 0.64% to 0.14%. The presence of NaEDTA in the samples may even increase levels of 7-dihydroxy methylnaltrexone formed.
  • FIG. 3A and FIG. 3B Effect of CaEDTA in methylnaltrexone solution on the formation of a methylnaltrexone degradant having an RRT 0.79 (“the 0.79 degradant”).
  • Calcium EDTA was not effective at inhibiting formation of the 0.79 degradant, and may increase levels of degradant formation.
  • FIG. 4 depicts identified degradants of methylnaltrexone, respective relative retention times (RRT), and associated catalysis and/or inhibitors of formation which have been identified.
  • compositions, kits, and products including provided formulations allow for extended storage periods and also for storage under favorable room temperature conditions. Compositions and kits and products containing provided formulations thus allow for improved delivery of therapeutics to subjects benefiting from use of methylnaltrexone.
  • provided formulations are useful to treat, prevent, delay, or decrease severity or incidence of side effects associated with opioid administration, including gastrointestinal dysfunction (e.g., constipation, bowel hypomotility, impaction, gastric hypomotility, GI sphincter constriction, increased sphincter tone, inhibition of gastrointestinal motility, inhibition of intestinal motility, inhibition of gastric emptying, delayed gastric emptying, incomplete evacuation, nausea, emesis (vomiting), bloating, abdominal distension), dysphoria, pruritis, urinary retention, depression of respiration, papillary constriction, cardiovascular effects, chest wall rigidity and cough suppression, depression of stress response, and immune suppression associated with use of narcotic analgesia, etc.
  • gastrointestinal dysfunction e.g., constipation, bowel hypomotility, impaction, gastric hypomotility, GI sphincter constriction, increased sphincter tone
  • inhibition of gastrointestinal motility inhibition of intestinal motility
  • inhibition of gastric emptying inhibition of gas
  • opioid administration can include, e.g., aberrant migration or proliferation of endothelial cells (e.g., vascular endothelial cells), increased angiogenesis, and increase in lethal factor production from opportunistic infectious agents (e.g., Pseudomonas aeruginosa ).
  • Formulations are useful for administration to patients receiving short term treatment with opioids (e.g., patients suffering from post-operative gastrointestinal dysfunction receiving short term opioid administration).
  • opioids e.g., patients suffering from post-operative gastrointestinal dysfunction receiving short term opioid administration.
  • Formulations are also useful for administration to subjects receiving chronic opioid administration (e.g., terminally ill patients receiving opioid therapy such as an AIDS patient, a cancer patient, a cardiovascular patient; subjects receiving chronic opioid therapy for pain management; subjects receiving opioid therapy for maintenance of opioid withdrawal).
  • ileus e.g., post-partum ileus, paralytic ileus
  • gastrointestinal dysfunction that develop following abdominal surgery (e.g., colectomy, including but not limited to, right hemicolectomy, left hemicolectomy, transverse hemicolectomy, colectomy takedown, and low anterior resection) such as post-operative ileus, and idiopathic constipation.
  • formulations are also useful in treatment of conditions including cancers involving angiogenesis, immune suppression, sickle cell anemia, vascular wounds, retinopathy, and treatment of inflammation associated disorders (e.g., irritable bowel syndrome), immune suppression, and chronic inflammation.
  • conditions including cancers involving angiogenesis, immune suppression, sickle cell anemia, vascular wounds, retinopathy, and treatment of inflammation associated disorders (e.g., irritable bowel syndrome), immune suppression, and chronic inflammation.
  • dose-concentrate refers to a pharmaceutical composition comprising a provided formulation, wherein the concentration of active agent(s) is higher than a typical unit dosage form concentration administered directly to a subject.
  • a dose-concentrate may be used as provided for administration to a subject, but is generally further diluted to a typical unit dosage form concentration in preparation for administration to a subject.
  • the entire volume of a dose-concentrate, or aliquots thereof, may be used in preparing unit dosage form(s) for treatment, for example, by the methods provided herein.
  • a dose-concentrate is about 2 fold, about 5-fold, about 10-fold, about 25-fold, about 50-fold, about 100-fold, or about 200-fold more concentrated than a unit dosage form.
  • a dose concentrate is about 50-fold, about 100-fold, or about 200-fold more concentrated than a unit dosage form.
  • an “effective amount” of a compound or pharmaceutically acceptable formulation can achieve a desired therapeutic and/or prophylactic effect.
  • an “effective amount” is at least a minimal amount of a compound, or formulation containing a compound, which is sufficient for treating one or more symptoms of a disorder or condition associated with modulation of peripheral ⁇ opioid receptors, such as side effects associated with opioid analgesic therapy (e.g., gastrointestinal dysfunction (e.g., dysmotility constipation, etc.), nausea, emesis, (e.g., vomiting), etc.).
  • an “effective amount” of a compound, or formulation containing a compound is sufficient for treating symptoms associated with, a disease associated with aberrant endogenous peripheral opioid or ⁇ opioid receptor activity (e.g., idiopathic constipation, ileus, etc.).
  • formulation refers to a composition that includes at least one pharmaceutically active compound (e.g., at least methylnaltrexone) in combination with one or more excipients or other pharmaceutical additives for administration to a subject.
  • pharmaceutically active compound e.g., at least methylnaltrexone
  • excipients and/or other pharmaceutical additives are typically selected with the aim of enabling a desired stability, release, distribution and/or activity of active compound(s) for applications.
  • subject means a mammal to whom a formulation or composition comprising a formulation is administered, and includes human and animal subjects, such as domestic animals (e.g., horses, dogs, cats, etc.).
  • domestic animals e.g., horses, dogs, cats, etc.
  • “Therapeutically active compound” or “active compound” refers to a substance, including a biologically active substance, that is useful for therapy (e.g., human therapy, veterinary therapy), including prophylactic and/or therapeutic treatment.
  • Therapeutically active compounds can be organic molecules that are drug compounds, peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecules linked to a protein, glycoprotein, steroid, nucleic acid, DNA, RNA, nucleotide, nucleoside, oligonucleotides, antisense oligonucleotides, lipid, hormone, and vitamin.
  • therapeutically active compounds can be any substance used as a medicine for treatment, prevention, delay, reduction or amelioration of a disease, condition, or disorder.
  • therapeutically active compounds useful in the formulations of the present invention are opioid antagonist compounds, opioid analgesic compounds, and the like. Further detailed description of compounds useful as therapeutically active compounds is provided below.
  • a therapeutically active compound includes a compound that increases the effect or effectiveness of a second compound, for example, by enhancing potency or reducing adverse effects of a second compound.
  • the terms “treat” or “treating,” as used herein, refers to partially or completely alleviating, inhibiting, delaying onset of, reducing the incidence of, ameliorating and/or relieving a disorder or condition, or one or more symptoms of the disorder, disease or condition.
  • unit dosage refers to a physically discrete unit of a formulation appropriate for a subject to be treated. It will be understood, however, that the total daily usage of a formulation of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active compound employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active compound employed; duration of the treatment; drugs and/or additional therapies used in combination or coincidental with specific compound(s) employed, and like factors well known in the medical arts.
  • the expression “dosage form” refers to means by which a formulation is stored and/or administered to a subject.
  • the formulation may be stored in a vial or syringe.
  • the formulation may also be stored in a container which protects the formulation from light (e.g., UV light).
  • a container or vial which itself is not necessarily protective from light may be stored in a secondary storage container (e.g., an outer box, bag, etc.) which protects the formulation from light.
  • methylnaltrexone includes N-methylnaltrexone and salts thereof.
  • Methylnaltrexone is described for example in U.S. Pat. Nos. 4,176,186; 4,719,215; 4,861,781; 5,102,887; 5,972,954; 6,274,591; United States published patent application numbers 20020028825 and 20030022909; and PCT publications WO99/22737 and WO98/25613; the contents of each of which are hereby incorporated by reference.
  • pharmaceutically acceptable salts include, but are not limited to, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, carbonate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, carboxylate, benzoate, glutamate, sulfonate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, selenate, and pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts of compounds.
  • pamoate i.e., 1,1′-methylene-bis-(2-hydroxy
  • salts of use in formulations of the invention are those that have been described for methylnaltrexone, e.g., methylnaltrexone bromide, etc.
  • the invention is not limited to these specific salts.
  • Other salts and mixtures thereof can be adapted and used in a dose formulation according to the invention so as to achieve the appropriate compound delivery profiles of the invention (e.g., chloride, sulfate, bisulfate, tartrate, nitrate, citrate, bitartrate, phosphate, malate, maleate, bromide, iodide, fumarate, sulfonate, carboxylate, or succinate salts, etc.).
  • peripheral opioid receptor antagonist e.g., methylnaltrexone
  • chemical and chiral derivatives thereof and other salts can be used, as appropriate.
  • the bromide salt of methylnaltrexone is also referred to, for example, N-methylnaltrexone bromide, N-methylnaltrexone hydrobromide, methylnaltrexone bromide, methylnaltrexone hydrobromide, naltrexone methobromide, N-methylnaltrexone, MNTX, SC-37359, MRZ-2663-BR, and N-cyclopropylmethylnoroxy-morphine-metho-bromide.
  • Methylnaltrexone is available in a powder form from Mallinckrodt Pharmaceuticals, St. Louis, Mo., provided as a white crystalline powder freely soluble in water. Its melting point is 254-256° C.
  • the invention provides formulations in a vial.
  • a formulation is provided in a vial containing a unit dosage of methylnaltrexone.
  • a formulation may comprise about 0.5 mg to about 200 mg methylnaltrexone bromide.
  • a unit dosage can contain from about 1 mg to about 80 mg, from about 5 mg to about 40 mg, or from about 8 mg to 12 mg to about 18 mg to about 24 mg.
  • Methylnaltrexone has chiral centers and can therefore occur as stereochemical isomers by virtue of the substituent placement on those chiral centers. Such stereochemical isomers are within the scope of the compounds contemplated for use in the present formulations.
  • compounds employed may be individual stereoisomers, as well as mixtures of stereoisomers.
  • methods of the present invention utilize compounds which are substantially pure stereoisomers. All tautomers are also intended to be encompassed within the compositions of the present invention.
  • R and S are used herein, as commonly used in organic chemistry nomenclature, to denote specific configuration of a chiral center.
  • the term “R” refers to “right” and is used to designate the configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
  • the term “S” or “left” is used to designate the configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
  • the priority of groups is based upon their atomic number (heaviest isotope first). A partial list of priorities and a discussion of stereochemistry is contained in the book: The Vocabulary of Organic Chemistry, Orchin, et al., John Wiley and Sons Inc., page 126 (1980), which is incorporated herein by reference in its entirety.
  • isolated R—N isomers of methylnaltrexone may be utilized in formulations and methods.
  • the designation of “R—N-isomer” of methylnaltrexone refers to such compounds in the (R) configuration with respect to the nitrogen.
  • Isolated isomer compounds include, but are not limited to, R—N isomer methylnaltrexone compounds described in U.S. patent application Ser. No. 11/441,395 filed May 25, 2006, published WO2006/127899, which is hereby incorporated herein by reference.
  • the active compound is an R—N isomer methylnaltrexone, or a salt thereof.
  • the R—N isomer of methylnaltrexone has been found in U.S. Ser. No. 11/441,395 to be an opioid antagonist.
  • isolated S—N isomers of methylnaltrexone may be utilized in formulations and methods.
  • the designation of “S—N-isomer” of methylnaltrexone refers to such compounds in the (S) configuration with respect to the nitrogen.
  • Isolated isomer compounds include, but are not limited to, S—N isomer of methylnaltrexone compounds described in U.S. patent application Ser. No. 11/441,452, filed May 25, 2006, published WO2006/127898, which is hereby incorporated by reference.
  • the active compound is an S—N isomer methylnaltrexone, or a salt thereof.
  • the S—N isomer of methylnaltrexone has been found in U.S. Ser. No. 11/441,452 to be an opioid agonist.
  • the methylnaltrexone of formulations described herein is a mixture of stereoisomers characterized in that it has an opioid antagonist effect.
  • the methylnaltrexone may be a mixture of R—N and S—N methylnaltrexone such that a mixture itself has an antagonist effect and would be useful for methods of use described herein for opioid antagonists.
  • R—N methylnaltrexone is used which is substantially free of S—N methylnaltrexone.
  • methylnaltrexone in the (R) configuration with respect to nitrogen.
  • Methods for determining the amount of (R)—N-isomer, present in a sample as compared to the amount of (S)—N-isomer present in that same sample, are described in detail in WO2006/127899, the entirety of which is hereby incorporated herein by reference.
  • methylnaltrexone contains 0.15%, 0.10%, or less (S)—N-isomer.
  • methylnaltrexone (or combination of methylnaltrexone and any other particular active agent) that is required to achieve a pharmaceutically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like.
  • a total daily dosage of methylnaltrexone (e.g., methylnaltrexone bromide) will typically be in the range 10-200 mg, preferably 20-100 mg for a 70 kg adult human.
  • a unit dosage formulation according to the invention will usually contain 1-250 mg of active compound (e.g., methylnaltrexone bromide) per unit, 5-100 mg of active compound per unit, 10-50 mg of active compound per unit, or about 8 mg or about 12 mg or about 24 mg of active compound per unit.
  • an effective amount of a methylnaltrexone for administration to a 70 kg adult human may comprise about 10 mg to about 50 mg of compound (e.g., methylnaltrexone bromide) per unit dosage, to be administered one or more times a day.
  • dose ranges set out above provide guidance for the administration of active compound to an adult.
  • the amount to be administered to for example, an infant or a baby can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
  • a formulation comprises methylnaltrexone, a calcium salt chelating agent, an isotonic agent, and a carrier.
  • a formulation comprises methylnaltrexone, a calcium salt chelating agent, an isotonic agent, a stabilizing agent, and a carrier.
  • the pH of the formulation is between about a pH of 2 to about a pH of 5.
  • the present invention provides formulations and methods for delivery of methylnaltrexone for improved storage and maintenance of pharmaceutical compositions.
  • the present invention provides formulations that are stable formulations for parenteral administration of methylnaltrexone compositions.
  • Formulations provided for parenteral administration may include sterile solution for injection, sterile suspension for injection, sterile emulsions, and dispersions.
  • formulations comprise methylnaltrexone, and a calcium salt-chelating agent in an isotonic solution.
  • formulations comprise methylnaltrexone, a calcium salt chelating agent, and a stabilizing agent in an isotonic solution.
  • provided formulations will include one or more active compound(s) together with one or more excipients, such as, for example, one or more chelating agents, a calcium ion, isotonic agents, carriers, buffers, co-solvents, diluents, preservatives, and/or surfactants, or combinations thereof.
  • active compound may comprise about 0.5 mg to about 200 mg methylnaltrexone bromide. In some embodiments, active compound may comprise about 1 mg to about 80 mg, from about 5 mg to about 40 mg, or about 8, or about 12 mg, about 16 mg, about 18 mg, or about 24 mg methylnaltrexone bromide.
  • the formulation comprises a chelating agent.
  • a chelating agent may be present in an amount from about 0.01 mg/mL to about 2 mg/mL or about 0.1 mg/mL to about 1 mg/mL in the formulation, or about 0.2 mg/mL to about 0.8 mg/mL of the formulation.
  • a chelating agent may be present in an amount from about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, or about 0.6 mg/mL, in the formulation.
  • a chelating agent is effective as inhibiting at least one degradant formation.
  • addition of at least one chelating agent is particularly useful in formulations that include methylnaltrexone, and provides protection from metal-catalyzed degradant production, and/or from precipitation.
  • Appropriate chelating agents include any pharmaceutically acceptable chelating agents and salts thereof.
  • chelating agents include, but are not limited to ethylenediaminetetraacetic acid (also synonymous with EDTA, edetic acid, versene acid, and sequestrene), and EDTA derivatives, such as sodium EDTA, and potassium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA, and related salts thereof.
  • ethylenediaminetetraacetic acid also synonymous with EDTA, edetic acid, versene acid, and sequestrene
  • EDTA derivatives such as sodium EDTA, and potassium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium
  • chelating agents include niacinamide and derivatives thereof and sodium desoxycholate and derivatives thereof, ethylene glycol-bis-(2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA) and derivatives thereof, diethylenetriaminepentaacetic acid (DTPA) and derivatives thereof, N,N-bis(carboxymethyl)glycine (NTA) and derivatives thereof, nitrilotriacetic acid and derivatives thereof.
  • Still other chelating agents include citric acid and derivatives thereof.
  • Citric acid also is known as citric acid monohydrate. Derivatives of citric acid include anhydrous citric acid and trisodium citrate-dihydrate.
  • chelating agent is selected from EDTA or an EDTA derivative or EGTA or an EGTA derivative.
  • chelating agent is EDTA disodium such as, for example, EDTA disodium hydrate.
  • a provided formulation comprises a calcium salt.
  • a calcium salt may be present in an amount from about 0.01 mg/mL to about 2 mg/mL or about 0.1 mg/mL to about 1 mg/mL in the formulation, or about 0.2 mg/mL to about 0.8 mg/mL of the formulation.
  • a calcium salt may be present in an amount from about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, or about 0.6 mg/mL, in the formulation.
  • a calcium ion is effective as inhibiting formation of at least one degradant.
  • addition of at least one calcium salt is particularly useful in formulations that include methylnaltrexone, and provides protection from metal-catalyzed degradant production, and/or from precipitation.
  • Appropriate calcium salts include any pharmaceutically acceptable calcium salts. Exemplary of calcium salts include, but are not limited to calcium chloride, calcium acetate, calcium citrate, calcium sulfate, etc.
  • a formulation comprises a calcium ion and a chelating agent included as a single component of the formulation.
  • a calcium salt chelating agent may be present in an amount from about 0.01 mg/mL to about 2 mg/mL or about 0.1 mg/mL to about 1 mg/mL in the formulation, or about 0.2 mg/mL to about 0.8 mg/mL of the formulation.
  • calcium salt chelating agent may be present in an amount from about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, or about 0.6 mg/mL, in the formulation.
  • a calcium salt chelating agent is particularly effective as inhibiting formation of at least one degradant.
  • addition of at least one calcium salt chelating agent is particularly useful in formulations that include methylnaltrexone, and provides protection from metal-catalyzed production of 2,2′ bis-methylnaltrexone, and 7-dihydroxy methylnaltrexone, and/or from precipitation.
  • the formulation comprises a calcium salt chelating agent.
  • Appropriate calcium salt chelating agents include any pharmaceutically acceptable chelating agents and calcium salts thereof.
  • Common calcium salt chelating agents include, but are not limited to calcium ethylenediaminetetra acetic acid (EDTA) and calcium salt EDTA derivatives, calcium ethylene glycol-bis-(2-aminoethyl)-N,N,N′,N′-tetraacetic acid (EGTA) and calcium salt EGTA derivatives, calcium diethylenetriaminepentaacetic acid (DTPA) and calcium salt DTPA derivatives, calcium N,N-bis(carboxymethyl)glycine (NTA) and calcium salt NTA derivatives, and calcium citrate and derivatives thereof.
  • EDTA calcium ethylenediaminetetra acetic acid
  • EGTA calcium ethylene glycol-bis-(2-aminoethyl)-N,N,N′,N′-tetraacetic acid
  • DTPA calcium diethylenetriaminepentaacetic acid
  • NTA N
  • chelating agent is selected from calcium EDTA or a calcium salt EDTA derivative or calcium EGTA or a calcium salt EGTA derivative.
  • chelating agent is calcium EDTA disodium such as, for example, calcium EDTA disodium hydrate.
  • a provided formulation comprises at least methylnaltrexone, a calcium salt chelating agent and an isotonic agent.
  • An isotonic agent useful in the present formulations can be any pharmaceutically acceptable isotonic agent. Common isotonic agents include agents selected from the group consisting of sodium chloride, mannitol, lactose, dextrose (hydrous or anhydrous), sucrose, glycerol, and sorbitol, and solutions of the foregoing.
  • the formulation comprises methylnaltrexone, an isotonic agent which is sodium chloride, and a calcium salt chelating agent which is calcium EDTA or a calcium salt EDTA derivative. In some embodiments, the EDTA is calcium EDTA disodium.
  • the formulation comprises at least methylnaltrexone, an isotonic agent, a calcium salt chelating agent and a carrier vehicle.
  • the carrier vehicle is an aqueous carrier.
  • Aqueous carrier vehicles are known in the art, and include, but are not limited to sterile water, water for injection, sodium chloride, Ringer's injection, isotonic dextrose injection, dextrose and lactated Ringers injection.
  • the formulation comprises water for injection.
  • formulations comprise methylnaltrexone or a pharmaceutically acceptable salt thereof, calcium EDTA or a calcium salt EDTA derivative, water for injection, and sodium chloride in an amount such that the final solution is isotonic (e.g., 0.1%, 0.25%, 0.45% 0.65%, 0.9% sodium chloride).
  • the sodium chloride is present in an isotonic amount, such that final concentration of sodium chloride is 0.65%.
  • formulations may contain such additional agents which comprise from about 1% to about 30% or about 1% to about 12% of the formulation or about 1% to about 10%, based upon total weight of the formulation.
  • additional agents may comprise from about 1%, about 2%, about 5%, about 8% or about 10% of the formulation, based upon total weight of the formulation.
  • additional ingredients are described below.
  • provided formulations comprise a stabilizing agent.
  • stabilizing agent may be present in an amount from about 0.01 mg/mL to about 2 mg/mL or about 0.05 mg/mL to about 1 mg/mL in the formulation, or about 0.1 mg/mL to about 0.8 mg/mL in the formulation.
  • stabilizing agent may be present in an amount from about 0.15 mg/mL, about 0.2 mg/mL, about 0.25 mg/mL, about 0.3 mg/mL, about 0.35 mg/mL, or about 0.4 mg/mL.
  • Suitable stabilizing agents for use in formulations of the invention include, but are not limited to glycine, benzoic acid, citric, glycolic, lactic, malic, and maleic acid.
  • the formulation comprises glycine.
  • glycine comprises glycine-HCl.
  • formulations comprise methylnaltrexone, calcium EDTA or a calcium salt EDTA derivative, water for injection, sodium chloride in an amount such that the final concentration is 6.5 mg/mL isotonic sodium chloride, and glycine such as glycine HCl.
  • a stabilizing agent is added to the formulation in an amount sufficient to adjust and maintain the pH of the formulation.
  • a stabilizing agent acts as a buffer function in addition to its role as a stabilizer.
  • a stabilizing agent may act as a buffer agent, so as to maintain the pH of the formulation.
  • the pH is between about pH 2.0 and about pH 6.0.
  • the pH of the formulation is between about pH 2.6 and about pH 5.0.
  • the pH of the formulation is between about pH 3.0 and about pH 4.0.
  • the pH of the formulation is between about pH 3.4 and about pH 3.6.
  • the pH of the formulation is about pH 3.5.
  • provided formulations comprise methylnaltrexone, calcium EDTA or a calcium salt EDTA derivative, water for injection, sodium chloride in an amount such that the final concentration is 6.5 mg/mL isotonic sodium chloride, glycine, and the pH of the formulation is between about pH 3.0 and about pH 4.0.
  • formulations comprise methylnaltrexone or a pharmaceutically acceptable salt thereof, calcium EDTA or a calcium salt EDTA derivative, water for injection, sodium chloride in an amount such that the final concentration is 6.5 mg/mL isotonic sodium chloride, glycine, and the pH of the formulation is between about pH 3.4 and about pH 3.6.
  • formulations comprise methylnaltrexone bromide, calcium EDTA or a calcium salt EDTA derivative, water for injection, sodium chloride in an amount such that the final concentration is 6.5 mg/mL isotonic sodium chloride, and glycine, and the formulation has a pH of about 3.5.
  • the pH is adjusted with glycine.
  • glycine is glycine HCl.
  • provided formulations comprise methylnaltrexone bromide, calcium EDTA, water for injection, isotonic sodium chloride, glycine HCl, and the formulation has a pH between about 3.4 and about 3.6.
  • provided formulations comprise methylnaltrexone bromide at a concentration about 20 mg/mL, calcium EDTA at a concentration about 0.4 mg/mL, sodium chloride in an amount such that the final concentration is 6.5 mg/mL isotonic sodium chloride, and glycine HCl at a concentration about 0.3 mg/mL, and the formulation has a pH of about 3.5.
  • formulations comprise methylnaltrexone bromide at a concentration about 10 mg/mL, calcium EDTA at a concentration about 0.2 mg/mL, sodium chloride in an amount such that the final concentration is 3.25 mg/mL isotonic sodium chloride, and glycine HCl at a concentration about 0.15 mg/mL, and the formulation has a pH of about 3.5.
  • pH adjustment may be performed with hydrochloric acid and/or sodium hydroxide.
  • formulations may comprise one or more additional agents for modification and/or optimization of release and/or absorption characteristics.
  • additional agents for modification and/or optimization of release and/or absorption characteristics.
  • incorporation of buffers, co-solvents, diluents, preservatives, and/or surfactants may facilitate dissolution, absorption, stability, and/or improved activity of active compound(s), and may be utilized in formulations of the invention.
  • the amount of additional agents in the formulation may optionally include: buffers about 10% to about 90%, co-solvents about 1% to about 50%, diluents about 1% to about 10%, preservative agents about 0.1% to about 8%, and/or surfactants about 1% to about 30%, based upon total weight of the formulation, as applicable.
  • Suitable co-solvents i.e., water miscible solvents
  • suitable co-solvents include, but are not limited to ethyl alcohol, propylene glycol.
  • Physiologically acceptable diluents may optionally be added to improve product characteristics.
  • Physiologically acceptable diluents are known in the art and include, but are not limited to, sugars, inorganic salts and amino acids, and solutions of any of the foregoing.
  • Representative examples of acceptable diluents include dextrose, mannitol, lactose, and sucrose, sodium chloride, sodium phosphate, and calcium chloride, arginine, tyrosine, and leucine, and the like, and aqueous solutions thereof.
  • Suitable preservatives are known in the art, and include, for example, benzyl alcohol, methyl paraben, propyl paraben, sodium salts of methyl paraben, thimerosal, chlorobutanol, phenol.
  • Suitable preservatives include but are not limited to: chlorobutanol (0.3-0.9% W/V), parabens (0.01-5.0% W/V), thimerosal (0.004-0.2% W/V), benzyl alcohol (0.5-5% W/V), phenol (0.1-1.0% W/V), and the like.
  • Suitable surfactants are also known in the art and include, e.g., poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters polyoxyethylene fatty acid esters, polyethylene glycol fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polysorbates, cetyl alcohol, glycerol fatty acid esters (e.g., triacetin, glycerol monostearate, and the like), polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, sucrose fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium, and the like, and combinations thereof.
  • the formulation may further comprise a surfactant.
  • the present invention provides dosage forms including unit dosage forms, dose-concentrates, etc. for parenteral administration.
  • Parenteral administration of provided formulations may include any of intravenous injection, intravenous infusion, intradermal, intralesional, intramuscular, subcutaneous injection or depot administration of a unit dose.
  • a unit dosage may or may not constitute a single “dose” of active compound(s), as a prescribing doctor may choose to administer more than one, less than one, or precisely one unit dosage in each dose (i.e., each instance of administration).
  • unit dosages may be administered once, less than once, or more than once a day, for example, once a week, once every other day (QOD), once a day, or 2, 3 or 4 times a day, more preferably 1 or 2 times per day.
  • QOD once every other day
  • unit dosages may be administered once, less than once, or more than once a day, for example, once a week, once every other day (QOD), once a day, or 2, 3 or 4 times a day, more preferably 1 or 2 times per day.
  • a provided dosage form is administered to a rehab patient (patients undergoing rehabilitation for orthopedic surgery, e.g. joint replacement) every other day or every day.
  • provided dosage is 12 mg methylnaltrexone.
  • a provided dosage form is administered to a chronic pain patient every other day or every day.
  • the pain is malignant or nonmalignant.
  • provided dosage is 12 mg methylnaltrexone.
  • the present invention provides variety of different dosage forms useful for parenteral administration, including, for example, a methylnaltrexone formulation provided in a container (e.g., a vial, ampoule, syringe, bag, dispenser, etc).
  • a container e.g., a vial, ampoule, syringe, bag, dispenser, etc.
  • the formulation is in a vial filled with methylnaltrexone solution, where the solution comprises at least one active compound which is methylnaltrexone, and a calcium salt chelating agent, in an isotonic solution.
  • a provided formulation is in a vial where the vial is filled with a provided formulation, as described above and herein.
  • provided formulation is in a vial from about 1 mL capacity to about 50 mL capacity.
  • a vial is about 1 mL, about 2 mL, about 5 mL, about 10 mL, about 25 mL or about 50 mL capacity.
  • a provided formulation is in a syringe or other dispenser filled a provided formulation as described above and herein.
  • a syringe or dispenser has a capacity from about 1 mL to about 20 mL. In some embodiments a syringe or dispenser has a capacity of about 1 mL, about 2 mL, about 2.5 mL, about 5 mL, about 7.5 mL, about 10 mL, about 15 mL, or about 20 mL. In some embodiments, a syringe or dispenser utilizes a hypodermic needle for administration of contents of the syringe or dispenser to a subject.
  • a syringe or dispenser utilized a needle-less adapter for transfer of contents of the container to a subject, or, alternatively to a second container for mixing and/or dilution of contents with another solution.
  • a dose-concentrate of a provided formulation can be in a sealed container holding an amount of the pharmaceutical formulation of the invention to be employed over a standard treatment interval such as immediately upon dilution, or up to 24 hours after dilution, as necessary.
  • a solution for intravenous administration can be prepared, for example, by adding a dose-concentrate formulation to a container (e.g., glass or plastic bottles, vials, ampoules) in combination with diluent so as to achieve desired concentration for administration.
  • the amount of dose concentrate added to diluent is a sufficient amount to treat a subject for a period ranging from about 6 hours to about 1 week, but preferably from about 6 or 12 hours to about 24 hours.
  • the container preferably also contains an empty space of sufficient size to permit (i) addition of aqueous solvent plus (ii) additional space as necessary to permit agitation and effect complete mixture of diluted dose concentrate formulation with the added aqueous solvent.
  • a container may be equipped with a penetrable or spikable top, for example, a rubber seal, such that aqueous solvent may be added by penetrating the seal with a hypodermic syringe or other type non-needle based, penetrable seal in order to transfer concentrate contents.
  • a provided formulation is provided in a spikable vial. In some embodiments, a provided formulation is provided in a 10 mL spikable vial.
  • Addition of aqueous solvent to a liquid dose concentrate may be conveniently used to form unit dosages of liquid pharmaceutical formulations by removing aliquot portions or entire contents of a dose concentrate for dilution.
  • Dose concentrate may be added to an intravenous (IV) container containing a suitable aqueous solvent.
  • IV intravenous
  • Useful solvents are standard solutions for injection as previously described (e.g., 5% dextrose, saline, lactated ringer's, or sterile water for injection, etc.).
  • Typical unit dosage IV bags are conventional glass or plastic containers having inlet and outlet means and having standard (e.g., 25 mL, 50 mL, 100 mL and 150 mL) capacities.
  • Dose concentrate solution of a pharmaceutical formulation of the invention is added to a unit dosage IV container in an amount to achieve a concentration of about 0.1 to about 1.0 mg of methylnaltrexone per mL and preferably from about 0.24 to about 0.48 mg per mL.
  • a vial may be a light container which protects contents from being exposed to light.
  • a vial may be packaged in any type of container which protects a formulation from being exposed to light (e.g., secondary packaging of a vial).
  • any other type of container may be a light protective container, or packaged within a light protective container.
  • Formulations of the present invention may be prepared in accordance with any of a variety of known techniques, for example as described by M. E. Aulton in “Pharmaceutics: The Science of Dosage Form Design” (1988) (Churchill Livingstone), the relevant disclosures of which are hereby incorporated by reference.
  • a provided formulation is prepared as follows: dry components of a formulation, including active compound (e.g., methylnaltrexone bromide), and calcium salt chelating agent (e.g., calcium EDTA) are dissolved in an appropriate solvent (e.g., an isotonic solution (e.g., isotonic sodium chloride for injection)).
  • an appropriate solvent e.g., an isotonic solution (e.g., isotonic sodium chloride for injection)
  • additional dry and/or wet ingredients e.g., solvent (e.g., water)
  • stabilizing agent e.g., sodium chloride for injection
  • additional dry and/or wet ingredients e.g., solvent (e.g., water)
  • stabilizing agent e.g., sodium chloride for injection
  • additional components e.g., solvent (e.g., water)
  • stabilizing agent e.g., sodium chloride for injection
  • surfactant e.g., sodium chloride
  • a provided formulation is prepared as follows: dry components of a formulation, including active compound (e.g., methylnaltrexone bromide), and calcium salt chelating agent (e.g., calcium EDTA) are dissolved in an appropriate solvent (e.g., an isotonic solution (e.g., isotonic sodium chloride for injection)).
  • active compound e.g., methylnaltrexone bromide
  • calcium salt chelating agent e.g., calcium EDTA
  • an appropriate solvent e.g., an isotonic solution (e.g., isotonic sodium chloride for injection)).
  • dry components of a formulation including active compound (e.g., methylnaltrexone bromide), and isotonic agent (e.g., sodium chloride) are dissolved in an aqueous solvent (e.g., water for injection) to generate an active compound in an isotonic solution (e.g., methylnaltrexone in isotonic sodium chloride for injection), followed by further addition and dissolution of calcium salt chelating agent (e.g., calcium EDTA) to the solution.
  • an aqueous solvent e.g., water for injection
  • an isotonic solution e.g., methylnaltrexone in isotonic sodium chloride for injection
  • calcium salt chelating agent e.g., calcium EDTA
  • glycine HCl may be utilized for addition to the solution to adjust pH to a desired pH (e.g., pH 3-4, pH 3.4-3.6, pH 3.5).
  • additional dry and/or wet ingredients e.g., solvent (e.g., water), stabilizing agent (e.g., glycine), or surfactant, may be added.
  • additional components such as stabilizing agents, surfactants are added to solvent prior to dissolving other components.
  • a provided formulation may be prepared under low oxygen conditions.
  • prepared formulations are incorporated into vials, ampoules, syringes, or dispensers, either alone, or with additional excipients.
  • Typical excipients added to a provided formulation include, but are not limited to surfactants, preservatives, diluents, buffers, co-solvents, etc.
  • Typical amounts of additional excipients added to a solution may include, for example, buffers about 10% to about 90%, co-solvents about 1% to about 50%, diluents about 1% to about 10%, preservative agents about 0.1% to about 8%, and surfactants about 1% to about 30%, based upon total weight.
  • a prepared formulation may be subjected to a filtration process in advance of packaging.
  • the filtration process may include, for example in the case of injection preparations, a sterilizing filtration and/or an ultra filtration of the processing solution before packaging to eliminate microorganisms or other contaminating matter from the processing solution.
  • a prepared formulation may be subjected to a distributing process to vials (e.g., clear glass vial, amber vials), ampoules, syringes, or dispensers (e.g., auto-dispensers).
  • the distributing process includes, for example in the case of vial packaging, a process distributing a suitable volume of the solution into vials taking the concentration of methylnaltrexone into consideration in order that contained products carry a desired amount of methylnaltrexone.
  • degradants occurring in methylnaltrexone solutions, as well as certain catalysis routes for formation of degradant(s). Still further, in certain respects, we have identified means to control formation of degradants, thus resulting in lower levels of degradants in liquid formulations containing methylnaltrexone. Provided in further detail in the Example 1 herein are methods and results of such identification, including structures of resulting degradant compounds. Additional Examples further provide characterization of prepared solutions, and identification of mechanisms of catalysis of formation and/or inhibition of formation of degradants.
  • determining the presence of one or more degradants in methylnaltrexone formulations are preferred for production of a methylnaltrexone formulation. Detection of individual degradant formation in a methylnaltrexone formulation by HPLC analysis and determining a formulation comprises one or more degradants below a specified level are preferred. In some embodiments the method provides analyzing a methylnaltrexone formulation by HPLC analysis and determining that the level of one or more specified degradants is not exceeded. Preferred concentration levels which are not exceeded for one or more degradants are described in the following paragraphs relating to levels of degradants in provided formulations.
  • methylnaltrexone formulations which inhibit formation of methylnaltrexone degradant(s), and confer improved stability characteristics to formulations and compositions and products containing methylnaltrexone formulations.
  • methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 2% of methylnaltrexone in the preparation following twelve or eighteen months of storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 1.5% of methylnaltrexone in the preparation following twelve or eighteen months of storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 1% of methylnaltrexone in the preparation following twelve or eighteen months of storage conditions.
  • Preferred storage conditions include room temperature storage.
  • methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 1.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 1% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In more particular embodiments, methylnaltrexone formulations are provided wherein the concentration of total degradation products does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration the aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of O-methyl methylnaltrexone (RRT 1.66) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration O-methyl methylnaltrexone (RRT 1.66) does not exceed about 0.25% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In more particular embodiments, methylnaltrexone formulations are provided wherein the concentration of O-methyl methylnaltrexone (RRT 1.66) does not exceed about 0.15% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations where the amount of S—N methyl naltrexone in the starting formulation is less than 0.5 wt % (relative to the total amount of methylnaltrexone) are provided wherein the concentration of the S-methylnaltrexone degradant product (RRT 0.89) does not exceed about 0.5% of methylnaltrexone in the preparation following six months of room temperature storage conditions. In some embodiments, methylnaltrexone formulations are provided wherein the concentration the S-methylnaltrexone degradant product (RRT 0.89) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations are provided wherein the concentration of the S-methylnaltrexone degradant product (RRT 0.89) does not exceed about 0.1% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • methylnaltrexone formulations wherein the concentration of total degradation products does not exceed about 1.25% of methylnaltrexone in the preparation following six months of room temperature storage conditions, the concentration 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.2% of methylnaltrexone, wherein the concentration 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.2% of methylnaltrexone, the concentration the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.2% of methylnaltrexone, the aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.2% of methylnaltrexone, the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.2% of methylnaltrexone, and the concentration of O-methyl methylnaltrexone (RRT 1.55) does not
  • methylnaltrexone formulations wherein the concentration of total degradation products does not exceed about 0.75% of methylnaltrexone in the preparation following six months of room temperature storage conditions, the concentration of 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.1% of methylnaltrexone, wherein the concentration of 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.1% of methylnaltrexone, the concentration of the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.15% of methylnaltrexone, the concentration of aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.05% of methylnaltrexone, the concentration of the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.1% of methylnaltrexone, and the concentration of O
  • methylnaltrexone formulations are provided wherein the concentration of 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.2% of methylnaltrexone, wherein the concentration of 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.2% of methylnaltrexone, the concentration of the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.2% of methylnaltrexone, and the concentration of the Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.2% of methylnaltrexone in the preparation following six months of room temperature storage conditions.
  • formulations include one or more other active compounds in addition to methylnaltrexone.
  • additional compound(s) may be included in one or more portion(s) that includes methylnaltrexone, may be missing from one or more portions that include methylnaltrexone, and/or may be included in one or more portions that does not include methylnaltrexone.
  • the invention encompasses formulations that deliver at least methylnaltrexone and at least one other active compound.
  • the invention encompasses formulations that deliver at least two independent portions of methylnaltrexone, and that further deliver at least one other active compound(s).
  • formulations comprise both an opioid and methylnaltrexone (e.g., a ⁇ opioid receptor antagonist).
  • opioid-associated side effects e.g., gastrointestinal effects (e.g., delayed gastric emptying, altered GI tract motility), etc.).
  • opioid compounds include, but are not limited to, alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, ethylmorphine, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucoronide, nalbuphine, nalorphine, nicomorphine, opium, oxycodone, oxymorphone, papavereturn, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, til
  • the opioid is at least one opioid selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, nicomorphine, oxycodone, oxymorphone, papavereturn, pentazocine, propiram, propoxyphene, sufentanil and/or tramadol.
  • opioid is at least one opioid selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, nicomorphine, oxycodone, oxymorphone, papavereturn, pentazocine, propiram,
  • the opioid is selected from morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl, tramadol, and mixtures thereof.
  • the opioid is loperamide.
  • the opioid is hydromorphone.
  • the opioid is a mixed agonist such as butorphanol.
  • the subjects are administered more than one opioid, for example, morphine and heroin or methadone and heroin.
  • the amount of additional active compound(s) present in combination compositions of this invention will typically be no more than the amount that would normally be administered in a composition comprising that active compound as the only therapeutic agent. In certain embodiments, the amount of additional active compound will range from about 50% to 100% of the amount normally present in a composition comprising that compound as the only therapeutic agent.
  • formulations may also be used in conjunction with and/or in combination with additional active compounds and/or conventional therapies for treatment of gastrointestinal dysfunction to aid in the amelioration of constipation and bowel dysfunction
  • conventional therapies include, but may not be limited to functional stimulation of the intestinal tract, stool softening agents, laxatives (e.g., diphelymethane laxatives, cathartic laxatives, osmotic laxatives, saline laxatives, etc), bulk forming agents and laxatives, lubricants, intravenous hydration, and nasogastric decompression.
  • the present invention provides formulations useful in antagonizing undesirable side effects of opioid analgesic therapy (e.g., gastrointestinal effects (e.g., delayed gastric emptying, altered GI tract motility), etc.).
  • formulations of the invention may be used to treat subjects having disease states that are ameliorated by binding ⁇ opioid receptors, or in any treatment wherein temporary suppression of the ⁇ opioid receptor system is desired (e.g., ileus, etc.).
  • methods of use of formulations are in human subjects.
  • administration of provided formulations may be advantageous for treatment, prevention, amelioration, delay or reduction of side effects of opioid administration, such as, for example, gastrointestinal dysfunction (e.g., inhibition of intestinal mobility, constipation, GI sphincter constriction, nausea, emesis (vomiting), biliary spasm, opioid bowel dysfunction, colic) dysphoria, pruritis, urinary retention, depression of respiration, papillary constriction, cardiovascular effects, chest wall rigidity and cough suppression, depression of stress response, and immune suppression associated with use of narcotic analgesia, etc, or combinations thereof.
  • gastrointestinal dysfunction e.g., inhibition of intestinal mobility, constipation, GI sphincter constriction, nausea, emesis (vomiting), biliary spasm, opioid bowel dysfunction, colic
  • dysphoria e.g., inhibition of intestinal mobility, constipation, GI sphincter constriction, nausea, emesis (vomiting),
  • Use of provided formulations may thus be beneficial from a quality of life standpoint for subjects receiving administration of opioids, as well as to reduce complications arising from chronic constipation, such as hemorrhoids, appetite suppression, mucosal breakdown, sepsis, colon cancer risk, and myocardial infarction.
  • provided formulations are useful for administration to a subject receiving short term opioid administration. In some embodiments, provided formulations are useful for administration to patients suffering from post-operative gastrointestinal dysfunction.
  • provided formulations are also useful for administration to subjects receiving chronic opioid administration (e.g., terminally ill patients receiving opioid therapy such as an AIDS patient, a cancer patient, a cardiovascular patient; subjects receiving chronic opioid therapy for pain management; subjects receiving opioid therapy for maintenance of opioid withdrawal).
  • the subject is a subject using opioid for chronic pain management.
  • the subject is a terminally ill patient.
  • the subject is a person receiving opioid withdrawal maintenance therapy.
  • Additional uses for formulations described herein may be to treat, reduce, inhibit, or prevent effects of opioid administration including, e.g., aberrant migration or proliferation of endothelial cells (e.g., vascular endothelial cells), increased angiogenesis, and increase in lethal factor production from opportunistic infectious agents (e.g., Pseudomonas aeruginosa ).
  • opioid administration including, e.g., aberrant migration or proliferation of endothelial cells (e.g., vascular endothelial cells), increased angiogenesis, and increase in lethal factor production from opportunistic infectious agents (e.g., Pseudomonas aeruginosa ).
  • Additional advantageous uses of provided formulations include treatment of opioid-induced immune suppression, inhibition of angiogenesis, inhibition of vascular proliferation, treatment of pain, treatment of inflammatory conditions such as inflammatory bowel syndrome, treatment of infectious diseases and diseases of the musculokeletal system such as osteoporosis, arthritis, osteitis, periostitis, myopathies, and treatment of autoimmune diseases.
  • formulations of the invention may be used in methods for preventing, inhibiting, reducing, delaying, diminishing or treating gastrointestinal dysfunction, including, but not limited to, irritable bowel syndrome, opioid-induced bowel dysfunction, colitis, post-operative, paralytic ileus, or postpartum ileus, nausea and/or vomiting, decreased gastric motility and emptying, inhibition of the stomach, and small and/or large intestinal propulsion, increased amplitude of non-propulsive segmental contractions, constriction of sphincter of Oddi, increased anal sphincter tone, impaired reflex relaxation with rectal distention, diminished gastric, biliary, pancreatic or intestinal secretions, increased absorption of water from bowel contents, gastro-esophageal reflux, gastroparesis, cramping, bloating, abdominal or epigastric pain and discomfort, constipation, idiopathic constipation, post-operative gastrointestinal dysfunction following abdominal surgery (e.g., colectomy (e.g., right hemi
  • formulations are also useful in treatment of conditions including cancers involving angiogenesis, immune suppression, sickle cell anemia, vascular wounds, and retinopathy, treatment of inflammation associated disorders (e.g., irritable bowel syndrome), immune suppression, chronic inflammation.
  • conditions including cancers involving angiogenesis, immune suppression, sickle cell anemia, vascular wounds, and retinopathy, treatment of inflammation associated disorders (e.g., irritable bowel syndrome), immune suppression, chronic inflammation.
  • veterinary applications e.g., treatment of domestic animals, e.g. horse, dogs, cats, etc.
  • use of provided formulations in veterinary applications analogous to those discussed above for human subjects is contemplated.
  • equine gastrointestinal motility such as colic and constipation
  • Resulting pain suffered by the horse with colic can result in a death-inducing shock, while a long-term case of constipation may also cause a horse's death.
  • Treatment of equines with peripheral opioid antagonists has been described, e.g., in U.S. Patent Publication No. 20050124657 published Jan. 20, 2005.
  • formulations of the present invention can be employed in combination therapies, that is, methylnaltrexone and compositions thereof, can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • Particular combination therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • therapies employed may achieve a desired effect for the same disorder (for example, a formulation may be administered concurrently with another compound used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic compounds which are normally administered to treat or prevent a particular disease, or condition are known as “appropriate for the disease, or condition, being treated”.
  • provided formulations and dosage forms are useful in preparation of medicaments, including, but not limited to medicaments useful in the treatment of side effects of opioid administration (e.g., gastrointestinal side effects (e.g., inhibition of intestinal motility, GI sphincter constriction, constipation, nausea, emesis) dysphoria, pruritis, etc.) or a combination thereof.
  • side effects of opioid administration e.g., gastrointestinal side effects (e.g., inhibition of intestinal motility, GI sphincter constriction, constipation, nausea, emesis) dysphoria, pruritis, etc.) or a combination thereof.
  • Provided formulations are useful for preparations of medicaments, useful in treatment of patients receiving short term opioid therapy (e.g., patients suffering from post-operative gastrointestinal dysfunction receiving short term opioid administration) or subjects using opioids chronically (e.g., terminally ill patients receiving opioid therapy such as an AIDS patient, a cancer patient, a cardiovascular patient; subjects receiving chronic opioid therapy for pain management; or subjects receiving opioid therapy for maintenance of opioid withdrawal).
  • short term opioid therapy e.g., patients suffering from post-operative gastrointestinal dysfunction receiving short term opioid administration
  • opioids chronically e.g., terminally ill patients receiving opioid therapy such as an AIDS patient, a cancer patient, a cardiovascular patient; subjects receiving chronic opioid therapy for pain management; or subjects receiving opioid therapy for maintenance of opioid withdrawal.
  • preparation of medicaments useful in the treatment of pain treatment of inflammatory conditions such as inflammatory bowel syndrome, treatment of infectious diseases, treatment of diseases of the musculokeletal system such as osteoporosis, arthritis, osteitis, periostitis, myopathies, treatment of autoimmune diseases and immune suppression, therapy of post-operative gastrointestinal dysfunction following abdominal surgery (e.g., colectomy (e.g., right hemicolectomy, left hemicolectomy, transverse hemicolectomy, colectomy takedown, low anterior resection), idiopathic constipation, and ileus), and treatment of disorders such as cancers involving angiogenesis, chronic inflammation and/or chronic pain, sickle cell anemia, vascular wounds, and retinopathy.
  • inflammatory conditions such as inflammatory bowel syndrome
  • infectious diseases treatment of diseases of the musculokeletal system
  • diseases of the musculokeletal system such as osteoporosis, arthritis, osteitis, periostitis, myopathies
  • compositions and/or kits may comprise a formulation and a container (e.g., a vial, ampoule, bottle, syringe, and/or dispenser package, or other suitable container).
  • a container e.g., a vial, ampoule, bottle, syringe, and/or dispenser package, or other suitable container.
  • provided kits may optionally further include a second container comprising a suitable aqueous carrier for dilution of the reconstitute for preparation of administration to a subject via IV administration.
  • contents of provided formulation container and solvent container combine to form a unit dosage form.
  • kits of the invention may comprise a formulation for administration of methylnaltrexone contained within a cartridge for use in conjunction with PCA device.
  • kits of the invention may comprise a formulation for administration of methylnaltrexone in a container suitable for frozen storage, and thawing prior to administration to a subject.
  • a container is a frozen intravenous bag.
  • a single container may comprise one or more compartments for containing lyophilized formulation, and/or appropriate aqueous carrier for dilution.
  • a single container may be appropriate for modification such that the container may receive a physical modification so as to allow combination of compartments and/or components of individual compartments.
  • a foil or plastic bag may comprise two or more compartments separated by a perforated seal which may be broken so as to allow combination of contents of two individual compartments once the signal to break the seal is generated.
  • a pharmaceutical pack or kit may thus comprise such multi-compartment containers including lyophilized formulation and appropriate solvent for reconstitution and/or appropriate aqueous carrier for dilution of reconstitute.
  • instructions for use are additionally provided in such kits.
  • a pharmaceutical kit comprises a formulation in a dilution package or container wherein a needle-less exchange mechanism allows for combination of formulation and with isotonic solution for preparation for intravenous administration.
  • a formulation of the invention may be utilized in conjunction with a MINIBAG® Plus diluent container system (Baxter), or an ADD VANTAGE® diluent container (Hospira) system.
  • instructions for use are additionally provided in such kits of the invention.
  • Such instructions may provide, generally, for example, instructions for dosage and administration.
  • instructions may further provide additional detail relating to specialized instructions for particular containers and/or systems for administration.
  • instructions may provide specialized instructions for use in conjunction and/or in combination with additional therapy.
  • the formulations of the invention may be used in conjunction with opioid analgesia administration, which may, optionally, comprise use of a patient controlled analgesia (PCA) device.
  • PCA patient controlled analgesia
  • instructions for use of provided formulations may comprise instructions for use in conjunction with PCA administration devices.
  • Method B (purity) Column: Prodigy ODS-3 15 cm ⁇ 4.6 mm, 3 ⁇ m particles (Phenomenex) Flow rate: 1.5 mL/min Detection: UV, 280 nm
  • Mobile phase Gradient as follows: Solvent A: 95:5 (v/v) 0.1% TFA in Water/Methanol Solvent B: 25:75 (v/v) 0.1% TFA in Water/Methanol Sample Solvent: 0.05M Dibasic Sodium Phosphate pH 6.8 Time (Min) % Mobile Phase A Gradient Program: 0 100 45 50 45.1 100 60 100
  • Method B (strength) Column: Prodigy ODS-3 15 cm ⁇ 4.6 mm, 3 ⁇ m particles (Phenomenex) Flow rate: 1.0 mL/min Detection: UV, 280 nm
  • Naltrexone base, S-methylnaltrexone, and O-methyl methylnaltrexone are each compounds found in initial production samples. Additional impurities/degradants formed and identified in methylnaltrexone formulations include 8-ketomethylnaltrexone bromide (RRT 0.49), the aldol dimer (RRT 1.77), O-methyl methylnaltrexone (RRT 1.66), and the 2,2 bis-methylnaltrexone (RRT 1.55), as well as additional degradants resulting at relative retention time of 0.67, 0.79 and 2.26.
  • RRT 0.49 8-ketomethylnaltrexone bromide
  • RRT 1.77 the aldol dimer
  • RRT 1.66 O-methyl methylnaltrexone
  • RRT 1.55 2,2 bis-methylnaltrexone
  • each of the three additional degradants were identified by NMR analysis following isolation from column eluates, and further characterized as described herein.
  • the 0.67 degradant has been identified as 7-dihydroxy methylnaltrexone;
  • the 0.79 degradant has been identified as a ring contracted form ((3R,4R,4aS,6aR,11bS)-6-carboxy-3-(cyclopropylmethyl)-4-a,6,8-trihydroxy-3-methyl-1,2,3,4,4a,5,6,6a-octahydro-4,11-methano[1]benzofuro[3′,2′:2,3]cyclopenta[1,2-c]pyridin-3-ium); and the 2.26 degradant has been identified as a Hoffman elimination product (see the following compound names, relative retention times, and associated structure; see also, FIG. 4 ).
  • results of stability studies in tables set forth in the following examples demonstrate resulting levels of each of the degradants identified in samples using HPLC analysis.
  • Stability test procedures used in the following examples include standard pharmaceutical stability studies according to ICH guidelines, under conditions of 25° C./60% relative humidity, 40° C./65% relative humidity, and/or 70° C.
  • FIG. 4 depicts three of the major resulting degradants, and the associate proposed mechanisms for catalysis of formation and/or methods of inhibition of formation which have been identified and further described in the examples that follow.
  • Fe3 + facilitates degradation of methylnaltrexone bromide in solution, resulting in formation of a 2,2′bis methylnaltrexone degradant.
  • Method B the 2,2′bis methylnaltrexone degradant results in a peak having an RRT about 1.55.
  • Fe 3+ is an ion that can get into the liquid formulation from several sources. For example, it can be leached from stainless steel process equipment, syringe needles, stoppers and amber vials.
  • EDTA as a metal chelating agent sequesters the available Fe 3+ in the solution, thereby preventing catalysis of the undesirable metal-catalyzed reactions.
  • Methylnaltrexone solutions were prepared in 0.9% NaCl, in the presence of iron and various concentrations of sodium EDTA and calcium EDTA.
  • sodium EDTA is EDTA disodium dihydrate, and the terms sodium EDTA, EDTA disodium dihydrate, and NaEDTA are used interchangeably throughout.
  • calcium EDTA is calcium EDTA disodium, and the terms calcium EDTA, calcium EDTA disodium, and CaEDTA are used interchangeably throughout.
  • Ca 2+ chelating agent provides additional inhibition of formation of a 7-dihydroxy-methylnaltrexone degradant as compared to Na 2+ chelating agent.
  • Methylnaltrexone solutions were prepared in 0.9% NaCl, in the presence of iron and various concentrations of sodium EDTA and calcium EDTA. Formation of 7-dihydroxy-methylnaltrexone was assessed at room temperature as well as at 40° C. Addition of calcium EDTA solution was highly effective at inhibiting formation of the 7-dihydroxy-methylnaltrexone degradant at both temperatures. See FIG. 2A and FIG. 2B . Use of calcium facilitates methylnaltrexone bromide stability in solution at room temperature.
  • Formation of the 0.79 methylnaltrexone degradant was lower at room temperature in the CaEDTA formulation described in Example 2 above as compared to refrigerated methylnaltrexone in saline solution.
  • Methylnaltrexone solution as described in Example 2 containing CaEDTA was compared to a control refrigerated methylnaltrexone solution in saline and formulations assessed for production of 0.79 degradant formation (room temperature CaEDTA 0.03% vs. refrigerated control saline 0.06%). See FIG. 3A and FIG. 3B .
  • Table 4 summarizes the formulation stability without pH control at 70° C.
  • the formulation has a pH of 5.6.
  • the data confirms that a formulation containing Ca EDTA does limit the formation of 0.67 and RRT 1.55 but does not reduce RRT 0.79. After only a few days RRT 0.79 grows to over 1.0%.
  • Each of the peaks resulting in the HPLC is represented in the table.
  • RRT 0.89 represents S-MNTX
  • RRT 1.17 represents naltrexone base
  • RRT 1.55 represent 2,2 bis methylnaltrexone
  • RRT 1.66 represents O-methyl-methylnaltrexone
  • RRT 1.77 represents aldol dimer formation
  • RRT 2.26 represents Hoffman elimination degradant formation.
  • BRL below recordable limit.
  • Table 5 summarizes the stability of prepared solutions. Additionally, Table 6 summarizes stability of prepared solutions at 40° C./75% Relative Humidity and at 70° C., with and without pH adjustment with glycine. We found that as additional glycine HCl is added to solution, the amount of degradant at RRT 0.79 formed is greatly reduced and confirms the stability of the formulation with respect to RRT 0.79 is stabilized by the presence of glycine. See Tables 5 and 6. TABLE 4 Stability data of MNTX 12 mg/vial, 0.28 mg/vial CaEDTA and 0.65% Sodium Chloride pH(5.6) at 70° C.
  • a solution containing methylnaltrexone including both CaEDTA and 0.3 mg/mL glycine HCl where the pH is adjusted to 3.4-3.6 will inhibit the formation of RRT 1.55 and greatly reduce the formation of degradants RRT 0.67 and RRT 0.79.
  • a room temperature liquid formulation consisting of methylnaltrexone, CaEDTA, 0.65% NaCl, 0.3 mg/mL glycine HCl with a pH to 3.5 may be developed as either a subcutaneous administration or intravenous administration formulation.
  • the levels of ingredients may be adapted to a final fill volume of 0.8 (or any other preferred final volume) to obtain the same concentrations. See Table 7.
  • TABLE 8 Formulation INGREDIENTS 12 Mg/VIAL A 16 Mg/VIAL A Methylnaltrexone 12 mg 16 mg 10 mg/mL bromide Calcium EDTA disodium 0.24 mg 0.0.32 mg 0.2 mg/mL dihydrate, NF Sodium Chloride 3.9 mg 5.20 mg 3.25 mg/mL Glycine HCL 0.18 mg 0.0.24 mg 0.15 mg/mL pH 3.5 pH 3.5 pH 3.5 Water for Injection, USP QS to 1.2 QS to 1.6 A 3 mL West flint glass vial with 13 mm West 4432/50 Fluorotec stopper and West 13 FO CS TE 3769 Blue Cap.
  • the levels of ingredients may be adapted to a final fill volume of 1.6 (or any other preferred final volume) to obtain the same concentrations. See Table 8.
  • Methylnaltrexone Formulation Comprising Sodium EDTA and citrate buffer.
  • Methylnaltrexone formulations consisting of methylnaltrexone, sodium EDTA, and sodium chloride in citrate buffer have been described (see US Patent Application Publication US2004/0266806A1, published Dec. 30, 2004). We have prepared solutions comprising the same components for stability comparison studies with our present formulations.
  • Formulations containing 20 mg/mL methylnaltrexone bromide in either A-0.7 mg/mL NaEDTA/pH 3.5 adjusted with citrate buffer; and B-0.4 mg/mL CaEDTA/0.65% NaCl/pH 3.5 adjusted with glycine buffer were prepared. Each of the formulations were assessed over time for presence of degradant formation, the results are shown in Table 11.
  • Formulations containing 5 mg/mL methylnaltrexone bromide (12 mg/vial or 24 mg/vial) were prepared as described in Example 12, below. Each of the formulations were assessed over time for presence of degradant formation, the results are shown in Table 12.
  • Identical preparations prepared as described in Example 4 were stored in parallel in vials having either a 13 mm WPS S2-F451 4432/50 Gray B2-40 Westar RS stopper (West Pharmaceutical Services) or a 13 mm S2-F451 RS D 777-1 RB2 40 stopper (Dalkyo Seiko, Ltd) under various conditions.
  • Each of the stoppers has a FluoroTec® fluorocarbon film; the Westar 4432/50 stopper is chlorobutyl rubber, while the RB2-40 RS D 777-1 stopper is bromobutyl rubber.
  • the presence of accumulation of degradant was assessed for each of the configurations (HPLC Method A). Table 14 depicts the results of these studies.
  • methylnaltrexone 5 mg/ml 0.8 mg of NaCL, 0.1 mg CaEDTA, 0.1 mg Glycine Hydrochloride, and water for injection was infused in 100 ml IV bags of 0.9% of Normal Saline and frozen at ⁇ 200 C.
  • the study was conducted for two concentrations of methylnaltrexone: 12 mg/100 ml and 24 mg/100 ml.
  • B/Braun bags NDC 0264-1800-32 with 0.9% of Normal Saline were used.
  • the first batch was the above methylnaltrexone IV formulation: 5 mg/ml methylnaltrexone, 0.8 mg of NaCL, 0.1 mg CaEDTA, 0.1 mg Glycine Hydrochloride infused in the 0.9% Normal Saline IV bag.
  • the second batch was just 5 mg/ml methylnaltrexone infused in 0.9% Normal Saline IV bag.
  • the bags were frozen and kept at ⁇ 20° C. The stability data showed that over a period of 2 months both batches were stable with no degradants formed. An additional benefit to the frozen bag storage is that no protection from light is required.
  • a room temperature methylnaltrexone formulation 20 mg/mL subcutaneous solution for injection CaEDTA formulation consists of 20 mg/mL methylnaltrexone bromide, 0.4 mg/mL edetate calcium disodium (CaEDTA), 0.3 mg/mL glycine hydrochloride and 0.65% sodium chloride in water for injection.
  • the product which is stable at room temperature storage conditions, is filled aseptically in single-use vials at 0.6 mL volume or 12 mg methylnaltrexone per vial to be administered subcutaneously.
  • the sodium chloride concentration is adjusted to 0.65% to maintain the tonicity of the formulation.
  • Such a room temperature formulation for subcutaneous administration was prepared as summarized in Tables 17A, 17B, and 17C below: TABLE 17A Methylnaltrexone 20 mg/mL Subcutaneous Solution for Injection, SC Commercial Formulation Strength 20 mg/mL Type Liquid Solution Container/Closure Vial 3 mL Stopper 13 mm mg/vial Methylnaltrexone 12 mg CaEDTA 0.32 Glycine HCl 0.24 NaCl 5.20 Overage 33% (0.2 ml) Processing Sterilization Aseptic Nitrogen Flush Yes Fill Volume 0.8 mL Dispensing Container Syringe Dilution None
  • the above formulation for subcutaneous administration may be dosed according to the following table. Patients whose weight falls outside the recited ranges may be dosed at 0.15 mg/kg. Patient Weight Pounds Kilograms Injection Volume Dose 84 to less than 38 to less than 62 0.4 mL 8 mg 136 136 to 251 62 to 114 0.6 mL 12 mg
  • the above formulation for subcutaneous administration dose may be reduced by one-half.
  • the present invention provides a pre-filled syringe containing a methylnaltrexone formulation in accordance with the present invention.
  • a pre-filled syringe is described below in Table 18.
  • TABLE 18 Pre-filled Syringe Concentration/Limits Active Ingredients Methylnaltrexone Bromide 20 mg/mL Excipients Calcium Disodium Edetate 0.4 mg/mL Glycine Hydrochloride 0.3 mg/mL Sodium Chloride 6.5 mg/mL Water for Injection (WFI)
  • Type 1 Needle Stainless steel AISI 304, CN18/10, 27G1/2, 5-bevel Soft needle shield: FM27/0 modified Rigid shell: Polypropylene SCF Stopper BD Basic raw material: bromobutyl rubber, 4023/50, grey Coating: contact side with Daiky
  • a bioequivalency study comparing the subcutaneous formulation described at Example 9 and a formulation containing only methylnaltrexone in saline was performed in an open-label, single-dose, randomized, 2-period, 2-sequence crossover, inpatient/outpatient study in healthy subjects conducted at a single investigational site. Doses were administered after an overnight fast of at least 10 hours. Healthy men and nonlactating and nonpregnant women aged 18 to 50 years were eligible for enrollment if all other qualifying criteria were met. At approximately 0800 on day 1 of periods 1 and 2, each subject received an SC injection containing 0.15 mg/kg of methylnaltrexone (the period 1, day ⁇ 1 weight was used to determine the dose to be administered).
  • Standard medium fat-meals served according to the clinic's schedule, could start 3 hours after test article administration.
  • Vital signs, ECGs, laboratory evaluations, and pharmacokinetic (PK) sample collection were completed at designated times on days 1, 2, and 3 of period 1 and 2 as per the study flowchart.
  • Each subject was to receive a single SC dose of 0.15 mg/kg of the assigned formulation of methylnaltrexone on day 1 of each period after an overnight fast of at least 10 hours.
  • the injection was administered SC into the upper arm and the same arm was to be used for each injection.
  • the injection site was to be healthy appearing skin. Every attempt was made to have the same person administer both formulations to each subject.
  • the dose was determined from the subject's weight on day ⁇ 1 of period 1.
  • the syringes were weighed before and after test article administration to verify the volume injected.
  • Each single dose was separated by a washout interval of at least 7 days. Blood samples were obtained for the determination of the pharmacokinetics of methylnaltrexone.
  • Blood samples (6 mL) were collected from an indwelling catheter or by direct venipuncture. If a catheter was used for blood collection, then approximately 0.5 mL of blood were to be discarded before collecting the sample at each sampling time. Blood samples were collected in each period on day 1 within 2 hours before test article administration and at 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours after test article administration. Results of pharmaceokinetic studies are set forth in Table 19, below.
  • the mean methylnaltrexone concentration-versus-time profile after the SC administration of a formulation of Example 9 was essentially identical to that seen with a saline formulation.
  • Plasma methylnaltrexone concentrations increased sharply in response to SC administration of either formulation, with a mean Cmax of 127 ng/mL for a provided formulation and 119 ng/mL for the saline formulation, observed mostly within the first hour (mean tmax of 0.34 h and 0.41 h, respectively).
  • methylnaltrexone formulations administered subcutaneously were evaluated in dogs. Pharmacokinetics of methylnaltrexone following a single subcutaneous 0.15 mg/kg dose in male beagle dogs. Eight male dogs (9.4-15 kg) were divided into two groups, four dogs per group. To both groups of dogs, 0.15 mg/kg methylnaltrexone in normal saline (Batch 1) was administered subcutaneously as a reference formulation during period 1. A week later, during period 2, Group 1 (SAN 1-4) received 0.15 mg/kg methylnaltrexone subcutaneously in saline containing 0.5 mg/vial Na.
  • EDTA and 0.6 mM Citrate received 0.15 mg/kg methylnaltrexone subcutaneously in saline containing 0.5 mg/vial Ca.
  • EDTA (Batch 3). Blood samples were drawn at 0 (predose), 0.0833, 0.167, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours after dosing, plasma was separated and assayed for methylnaltrexone content.
  • the present invention provides a methylnaltrexone formulation for intravenous administration.
  • Provided intravenous formulations can be prepared in 12 mg/vial or 24 mg/vial concentrations. Both 12 mg/vial and 24 mg/vial strengths use a 5 mg/mL concentration of methylnaltrexone.
  • provided intravenous formulations utilize a 10 mL spikable vial designed to be used with Baxter mini-bags or any other spikable infusion system.
  • provided formulations were subjected to terminal sterilization by heating at 121° C. for 15 minutes.
  • Formulations prepared in 12 mg/vial or 24 mg/vial concentrations are set forth in Tables 20A and 20B, respectively, below. Such formulations can be administered at doses of 24 mg, or also, for example, 0.3 mg/kg, every 6 hours as a 20-minute infusion. In certain embodiments, such administration is continued for 3 days (total of 12 doses). Each methylnaltrexone formulation is diluted to 50 mL and administered using a calibrated pump.
  • fill volume is at least 2.6 mL for a 2.4 mL extractable volume, and at least 5.1 mL for a 4.8 mL extractable volume.
  • Table 20C describes vial contents dilution when using a traditional syringe or a spikable vial.
  • a provided intravenous formulation is administered to a patient 90 minutes post surgery, where the surgery is hernia repair.
  • the hernia repair patient is administered opioids via PCA pump.
  • Such formulations can be administered at doses of 12 mg or 24 mg, or also, for example, 0.3 mg/kg, every 6 hours as a 20-minute infusion. In certain embodiments, such administration is continued for 10 days, the patient is discharged, or 24 hours post-bowel movement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
US11/890,034 2006-08-04 2007-08-03 Formulations for parenteral delivery of compounds and uses thereof Abandoned US20080070975A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/890,034 US20080070975A1 (en) 2006-08-04 2007-08-03 Formulations for parenteral delivery of compounds and uses thereof
US12/726,113 US20100249169A1 (en) 2006-08-04 2010-03-17 Formulations for parenteral delivery of compounds and uses thereof
US14/105,805 US20150025100A1 (en) 2006-08-04 2013-12-13 Formulations for parenteral delivery of compounds and uses thereof
US15/158,967 US20160338946A1 (en) 2006-08-04 2016-05-19 Formulations for parenteral delivery of compounds and uses thereof
US16/514,722 US20200179270A1 (en) 2006-08-04 2019-07-17 Formulations for parenteral delivery of compounds and uses thereof
US17/357,023 US20220023200A1 (en) 2006-08-04 2021-06-24 Formulations for parenteral delivery of compounds and uses thereof
US18/244,446 US20230414490A1 (en) 2006-08-04 2023-09-11 Formulations for parenteral delivery of compounds and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83557406P 2006-08-04 2006-08-04
US11/890,034 US20080070975A1 (en) 2006-08-04 2007-08-03 Formulations for parenteral delivery of compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/726,113 Continuation US20100249169A1 (en) 2006-08-04 2010-03-17 Formulations for parenteral delivery of compounds and uses thereof

Publications (1)

Publication Number Publication Date
US20080070975A1 true US20080070975A1 (en) 2008-03-20

Family

ID=39033508

Family Applications (7)

Application Number Title Priority Date Filing Date
US11/890,034 Abandoned US20080070975A1 (en) 2006-08-04 2007-08-03 Formulations for parenteral delivery of compounds and uses thereof
US12/726,113 Abandoned US20100249169A1 (en) 2006-08-04 2010-03-17 Formulations for parenteral delivery of compounds and uses thereof
US14/105,805 Abandoned US20150025100A1 (en) 2006-08-04 2013-12-13 Formulations for parenteral delivery of compounds and uses thereof
US15/158,967 Granted US20160338946A1 (en) 2006-08-04 2016-05-19 Formulations for parenteral delivery of compounds and uses thereof
US16/514,722 Abandoned US20200179270A1 (en) 2006-08-04 2019-07-17 Formulations for parenteral delivery of compounds and uses thereof
US17/357,023 Abandoned US20220023200A1 (en) 2006-08-04 2021-06-24 Formulations for parenteral delivery of compounds and uses thereof
US18/244,446 Pending US20230414490A1 (en) 2006-08-04 2023-09-11 Formulations for parenteral delivery of compounds and uses thereof

Family Applications After (6)

Application Number Title Priority Date Filing Date
US12/726,113 Abandoned US20100249169A1 (en) 2006-08-04 2010-03-17 Formulations for parenteral delivery of compounds and uses thereof
US14/105,805 Abandoned US20150025100A1 (en) 2006-08-04 2013-12-13 Formulations for parenteral delivery of compounds and uses thereof
US15/158,967 Granted US20160338946A1 (en) 2006-08-04 2016-05-19 Formulations for parenteral delivery of compounds and uses thereof
US16/514,722 Abandoned US20200179270A1 (en) 2006-08-04 2019-07-17 Formulations for parenteral delivery of compounds and uses thereof
US17/357,023 Abandoned US20220023200A1 (en) 2006-08-04 2021-06-24 Formulations for parenteral delivery of compounds and uses thereof
US18/244,446 Pending US20230414490A1 (en) 2006-08-04 2023-09-11 Formulations for parenteral delivery of compounds and uses thereof

Country Status (25)

Country Link
US (7) US20080070975A1 (es)
EP (1) EP2046388B1 (es)
JP (1) JP5356231B2 (es)
KR (1) KR20090040248A (es)
CN (2) CN101405031B (es)
AR (1) AR063471A1 (es)
AU (1) AU2007281984B8 (es)
BR (1) BRPI0708965B8 (es)
CA (1) CA2646901C (es)
EC (1) ECSP088752A (es)
ES (1) ES2655863T3 (es)
GT (1) GT200800185A (es)
HN (1) HN2008001464A (es)
IL (2) IL194182A (es)
MX (1) MX2008011993A (es)
NO (1) NO343701B1 (es)
NZ (1) NZ597260A (es)
PE (1) PE20080741A1 (es)
PH (1) PH12013500801A1 (es)
PL (1) PL2046388T3 (es)
RU (1) RU2539387C2 (es)
SG (1) SG174030A1 (es)
TW (1) TWI489984B (es)
WO (1) WO2008019115A2 (es)
ZA (1) ZA200808203B (es)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064743A1 (en) * 2006-09-08 2008-03-13 Wyeth Dry powder compound formulations and uses thereof
US20080064744A1 (en) * 2006-08-04 2008-03-13 Wyeth 6-Carboxy-normorphinan derivatives, synthesis and uses thereof
US20100087472A1 (en) * 1997-11-03 2010-04-08 Foss Joseph F Use of methylnaltrexone and related compound to treat constipation in chronic opioid users
US20100099699A1 (en) * 2007-03-29 2010-04-22 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100105911A1 (en) * 2005-05-25 2010-04-29 Boyd Thomas A (S)-N-methylnal trexone
US20100120813A1 (en) * 2008-09-30 2010-05-13 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100261744A1 (en) * 2003-04-08 2010-10-14 Progenics Pharmaceuticals, Inc. Pharmaceutical formulation
US20100305323A1 (en) * 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
US20100311781A1 (en) * 2005-05-25 2010-12-09 Progenics Pharmaceuticals, Inc. Synthesis of r-n-methylnaltrexone
US20110100099A1 (en) * 2008-02-06 2011-05-05 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US20110190331A1 (en) * 2007-03-29 2011-08-04 Avey Alfred A Peripheral opioid receptor antagonists and uses thereof
US8524276B2 (en) * 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US20140242061A1 (en) * 2009-07-28 2014-08-28 Shire Human Genetic Therapies, Inc. Compositions and methods for treating gaucher disease
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US10041137B2 (en) 2000-08-18 2018-08-07 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20180264083A1 (en) * 2017-03-16 2018-09-20 University Of Rochester Erythropoietin for Gastrointestinal Dysfunction
US10213424B2 (en) 2013-03-14 2019-02-26 Fresenius Kabi Deutschland Gmbh Morphine formulations
US10214338B2 (en) 2013-03-14 2019-02-26 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099410A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r)-8-keto-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
AU2016201221B2 (en) * 2008-09-30 2017-08-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
AU2013203119B2 (en) * 2008-09-30 2015-12-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
ES2753981T3 (es) 2010-10-21 2020-04-15 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para uso
CN102525911B (zh) * 2012-03-20 2013-09-18 南京臣功制药股份有限公司 一种溴甲纳曲酮注射液及其制备方法
CN103239452A (zh) * 2013-01-25 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种溴甲基纳曲酮药物组合物
CN105769755A (zh) * 2014-12-23 2016-07-20 北大方正集团有限公司 一种溴甲纳曲酮注射液及其制备方法
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
CN110960486B (zh) * 2018-09-29 2022-05-13 北京凯因科技股份有限公司 一种溴甲纳曲酮注射液组合物
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN111303093A (zh) * 2020-02-21 2020-06-19 重庆医药高等专科学校 一种溴甲纳曲酮杂质的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266806A1 (en) * 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221707D0 (en) * 1992-10-15 1992-12-02 Smithkline Beecham Plc Pharmaceutical composition
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
CN1211085C (zh) * 1999-09-29 2005-07-20 宝洁公司 稳定性改善的组合物
JP4683842B2 (ja) * 2002-03-14 2011-05-18 ユーロ−セルティーク エス．エイ． 塩酸ナルトレキソン組成物
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266806A1 (en) * 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087472A1 (en) * 1997-11-03 2010-04-08 Foss Joseph F Use of methylnaltrexone and related compound to treat constipation in chronic opioid users
US10041137B2 (en) 2000-08-18 2018-08-07 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20100261746A1 (en) * 2003-04-08 2010-10-14 Progenics Pharmaceuticals, Inc. Pharmaceutical formulation
US20100261745A1 (en) * 2003-04-08 2010-10-14 Progenics Pharmaceuticals, Inc. Pharmaceutical formulation
EP1615646B2 (en) † 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US10376584B2 (en) 2003-04-08 2019-08-13 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US20100261744A1 (en) * 2003-04-08 2010-10-14 Progenics Pharmaceuticals, Inc. Pharmaceutical formulation
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US20100311781A1 (en) * 2005-05-25 2010-12-09 Progenics Pharmaceuticals, Inc. Synthesis of r-n-methylnaltrexone
US20100105911A1 (en) * 2005-05-25 2010-04-29 Boyd Thomas A (S)-N-methylnal trexone
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
US8916581B2 (en) 2005-05-25 2014-12-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US7501434B2 (en) 2006-08-04 2009-03-10 Wyeth 6-carboxy-normorphinan derivatives, synthesis and uses thereof
US20080064744A1 (en) * 2006-08-04 2008-03-13 Wyeth 6-Carboxy-normorphinan derivatives, synthesis and uses thereof
US20080064743A1 (en) * 2006-09-08 2008-03-13 Wyeth Dry powder compound formulations and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US20100099699A1 (en) * 2007-03-29 2010-04-22 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100305323A1 (en) * 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US20110190331A1 (en) * 2007-03-29 2011-08-04 Avey Alfred A Peripheral opioid receptor antagonists and uses thereof
US8772310B2 (en) 2007-03-29 2014-07-08 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8916706B2 (en) * 2008-02-06 2014-12-23 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US20110100099A1 (en) * 2008-02-06 2011-05-05 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8420663B2 (en) 2008-09-30 2013-04-16 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
EP3608322A1 (en) 2008-09-30 2020-02-12 Wyeth LLC Syringe containing nmtx bromide
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100120813A1 (en) * 2008-09-30 2010-05-13 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8822490B2 (en) 2008-09-30 2014-09-02 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8455644B2 (en) 2008-09-30 2013-06-04 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20140242061A1 (en) * 2009-07-28 2014-08-28 Shire Human Genetic Therapies, Inc. Compositions and methods for treating gaucher disease
US11571466B2 (en) * 2009-07-28 2023-02-07 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10376505B2 (en) 2010-03-11 2019-08-13 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US10307417B2 (en) 2010-03-11 2019-06-04 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US8956651B2 (en) 2010-03-11 2015-02-17 Wyeth, Llc Oral formulations and lipophilic salts of methylnal trexone
US8524276B2 (en) * 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US10507206B2 (en) 2010-03-11 2019-12-17 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US9314461B2 (en) 2010-03-11 2016-04-19 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US11214426B2 (en) 2013-03-14 2022-01-04 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
US10214338B2 (en) 2013-03-14 2019-02-26 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
US10781027B2 (en) 2013-03-14 2020-09-22 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
US10213424B2 (en) 2013-03-14 2019-02-26 Fresenius Kabi Deutschland Gmbh Morphine formulations
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
US20180264083A1 (en) * 2017-03-16 2018-09-20 University Of Rochester Erythropoietin for Gastrointestinal Dysfunction

Also Published As

Publication number Publication date
WO2008019115A3 (en) 2008-07-03
TW200815007A (en) 2008-04-01
IL194182A (en) 2013-08-29
CN101405031A (zh) 2009-04-08
SG174030A1 (en) 2011-09-29
US20230414490A1 (en) 2023-12-28
CA2646901A1 (en) 2008-02-14
PE20080741A1 (es) 2008-08-06
NZ597260A (en) 2013-07-26
US20100249169A1 (en) 2010-09-30
GT200800185A (es) 2009-08-27
IL221795A0 (en) 2012-10-31
BRPI0708965A2 (pt) 2011-06-28
MX2008011993A (es) 2008-10-01
RU2539387C2 (ru) 2015-01-20
AU2007281984A1 (en) 2008-02-14
RU2008138266A (ru) 2010-03-27
JP2009545603A (ja) 2009-12-24
EP2046388B1 (en) 2017-12-13
US20150025100A1 (en) 2015-01-22
PH12013500801B1 (en) 2014-10-20
PH12013500801A1 (en) 2014-10-20
PL2046388T3 (pl) 2018-04-30
AU2007281984B8 (en) 2014-01-09
US20160338946A1 (en) 2016-11-24
US20220023200A1 (en) 2022-01-27
JP5356231B2 (ja) 2013-12-04
KR20090040248A (ko) 2009-04-23
TWI489984B (zh) 2015-07-01
CA2646901C (en) 2015-12-22
CN102846613A (zh) 2013-01-02
CN101405031B (zh) 2012-10-10
WO2008019115A2 (en) 2008-02-14
BRPI0708965B8 (pt) 2021-05-25
AR063471A1 (es) 2009-01-28
NO343701B1 (no) 2019-05-13
AU2007281984B2 (en) 2013-12-05
ES2655863T3 (es) 2018-02-22
HN2008001464A (es) 2011-03-30
ZA200808203B (en) 2010-06-30
BRPI0708965B1 (pt) 2020-01-07
IL221795B (en) 2018-06-28
NO20083973L (no) 2009-01-06
US20200179270A1 (en) 2020-06-11
ECSP088752A (es) 2008-10-31
EP2046388A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
US20230414490A1 (en) Formulations for parenteral delivery of compounds and uses thereof
US20120059025A1 (en) Dry powder compound formulations and uses thereof
US10376584B2 (en) Stable pharmaceutical formulations of methylnaltrexone
AU2013263750B2 (en) Formulations for parenteral delivery of compounds and uses thereof
US20200113851A1 (en) Midodrine hydrochloride oral solution and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHAH, SYED M.;OFSLAGER, CHRISTIAN;FAWZI, MAHDI B.;AND OTHERS;REEL/FRAME:020769/0665;SIGNING DATES FROM 20071025 TO 20071109

AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAZHINA, NATALIYA;REEL/FRAME:020802/0767

Effective date: 20080408

AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAZHINA, NATALIYA;REEL/FRAME:020932/0994

Effective date: 20080506

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION